Combined administration of captopril with an antihypertensive Val-Tyr di-peptide to spontaneously hypertensive rats attenuates the blood pressure lowering effect

Toshiro Matsui, Xiao Lin Zhu, Keisuke Watanabe, Keisuke Tanaka, Yoko Kusano, Kiyoshi Matsumoto

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Some di-peptides have been proven to exert an antihypertensive effect in mild-hypertensive subjects. The aim of this study was to clarify whether combined administration of an ACE inhibitor, captopril, with an antihypertensive di-peptide Val-Tyr (VY) would alter their potent antihypertensive effects in spontaneously hypertensive rats (SHRs). Single oral administration of captopril (2.5 mg/kg), VY (25 mg/kg), or captopril (2.5 mg/kg) + VY (25 mg/kg) to 18-week-old male SHRs was performed. Systolic blood pressure (SBP) was measured up to 9 h, and plasma captopril concentrations were determined. A transport study of captopril and/or VY across living rat jejunum from SHRs was also performed to evaluate the kinetics of absorption. Combined administration of captopril with VY failed to lower the BP during the 9-h experiment. A transport study of captopril or VY revealed that VY inhibited captopril transport, and vice versa, in a competitive manner and exhibited an approximately 1/3-fold lower Ki value for captopril compared with that for VY; indicating that both compounds compete for the same membrane transport pathway. A 50% decrease in plasma captopril levels by combined administration with VY supported that the attenuation of the BP lowering effect was due to inhibition of captopril uptake by VY. Consequently, our findings suggest that subjects treated with ACE inhibitors for hypertension should avoid combined-intake with antihypertensive foods that are rich in small peptides due to the competitive inhibition of drug uptake by these peptides.

Original languageEnglish
Pages (from-to)2492-2498
Number of pages7
JournalLife Sciences
Volume79
Issue number26
DOIs
Publication statusPublished - Nov 25 2006
Externally publishedYes

Fingerprint

valyltyrosine
Pressure effects
Captopril
Blood pressure
Inbred SHR Rats
Antihypertensive Agents
Rats
Blood Pressure
Peptides
Angiotensin-Converting Enzyme Inhibitors
Plasmas
Jejunum

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Combined administration of captopril with an antihypertensive Val-Tyr di-peptide to spontaneously hypertensive rats attenuates the blood pressure lowering effect. / Matsui, Toshiro; Zhu, Xiao Lin; Watanabe, Keisuke; Tanaka, Keisuke; Kusano, Yoko; Matsumoto, Kiyoshi.

In: Life Sciences, Vol. 79, No. 26, 25.11.2006, p. 2492-2498.

Research output: Contribution to journalArticle

Matsui, Toshiro ; Zhu, Xiao Lin ; Watanabe, Keisuke ; Tanaka, Keisuke ; Kusano, Yoko ; Matsumoto, Kiyoshi. / Combined administration of captopril with an antihypertensive Val-Tyr di-peptide to spontaneously hypertensive rats attenuates the blood pressure lowering effect. In: Life Sciences. 2006 ; Vol. 79, No. 26. pp. 2492-2498.
@article{5deb26209f3349f9b5ac11f6cdcdd915,
title = "Combined administration of captopril with an antihypertensive Val-Tyr di-peptide to spontaneously hypertensive rats attenuates the blood pressure lowering effect",
abstract = "Some di-peptides have been proven to exert an antihypertensive effect in mild-hypertensive subjects. The aim of this study was to clarify whether combined administration of an ACE inhibitor, captopril, with an antihypertensive di-peptide Val-Tyr (VY) would alter their potent antihypertensive effects in spontaneously hypertensive rats (SHRs). Single oral administration of captopril (2.5 mg/kg), VY (25 mg/kg), or captopril (2.5 mg/kg) + VY (25 mg/kg) to 18-week-old male SHRs was performed. Systolic blood pressure (SBP) was measured up to 9 h, and plasma captopril concentrations were determined. A transport study of captopril and/or VY across living rat jejunum from SHRs was also performed to evaluate the kinetics of absorption. Combined administration of captopril with VY failed to lower the BP during the 9-h experiment. A transport study of captopril or VY revealed that VY inhibited captopril transport, and vice versa, in a competitive manner and exhibited an approximately 1/3-fold lower Ki value for captopril compared with that for VY; indicating that both compounds compete for the same membrane transport pathway. A 50{\%} decrease in plasma captopril levels by combined administration with VY supported that the attenuation of the BP lowering effect was due to inhibition of captopril uptake by VY. Consequently, our findings suggest that subjects treated with ACE inhibitors for hypertension should avoid combined-intake with antihypertensive foods that are rich in small peptides due to the competitive inhibition of drug uptake by these peptides.",
author = "Toshiro Matsui and Zhu, {Xiao Lin} and Keisuke Watanabe and Keisuke Tanaka and Yoko Kusano and Kiyoshi Matsumoto",
year = "2006",
month = "11",
day = "25",
doi = "10.1016/j.lfs.2006.08.013",
language = "English",
volume = "79",
pages = "2492--2498",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "26",

}

TY - JOUR

T1 - Combined administration of captopril with an antihypertensive Val-Tyr di-peptide to spontaneously hypertensive rats attenuates the blood pressure lowering effect

AU - Matsui, Toshiro

AU - Zhu, Xiao Lin

AU - Watanabe, Keisuke

AU - Tanaka, Keisuke

AU - Kusano, Yoko

AU - Matsumoto, Kiyoshi

PY - 2006/11/25

Y1 - 2006/11/25

N2 - Some di-peptides have been proven to exert an antihypertensive effect in mild-hypertensive subjects. The aim of this study was to clarify whether combined administration of an ACE inhibitor, captopril, with an antihypertensive di-peptide Val-Tyr (VY) would alter their potent antihypertensive effects in spontaneously hypertensive rats (SHRs). Single oral administration of captopril (2.5 mg/kg), VY (25 mg/kg), or captopril (2.5 mg/kg) + VY (25 mg/kg) to 18-week-old male SHRs was performed. Systolic blood pressure (SBP) was measured up to 9 h, and plasma captopril concentrations were determined. A transport study of captopril and/or VY across living rat jejunum from SHRs was also performed to evaluate the kinetics of absorption. Combined administration of captopril with VY failed to lower the BP during the 9-h experiment. A transport study of captopril or VY revealed that VY inhibited captopril transport, and vice versa, in a competitive manner and exhibited an approximately 1/3-fold lower Ki value for captopril compared with that for VY; indicating that both compounds compete for the same membrane transport pathway. A 50% decrease in plasma captopril levels by combined administration with VY supported that the attenuation of the BP lowering effect was due to inhibition of captopril uptake by VY. Consequently, our findings suggest that subjects treated with ACE inhibitors for hypertension should avoid combined-intake with antihypertensive foods that are rich in small peptides due to the competitive inhibition of drug uptake by these peptides.

AB - Some di-peptides have been proven to exert an antihypertensive effect in mild-hypertensive subjects. The aim of this study was to clarify whether combined administration of an ACE inhibitor, captopril, with an antihypertensive di-peptide Val-Tyr (VY) would alter their potent antihypertensive effects in spontaneously hypertensive rats (SHRs). Single oral administration of captopril (2.5 mg/kg), VY (25 mg/kg), or captopril (2.5 mg/kg) + VY (25 mg/kg) to 18-week-old male SHRs was performed. Systolic blood pressure (SBP) was measured up to 9 h, and plasma captopril concentrations were determined. A transport study of captopril and/or VY across living rat jejunum from SHRs was also performed to evaluate the kinetics of absorption. Combined administration of captopril with VY failed to lower the BP during the 9-h experiment. A transport study of captopril or VY revealed that VY inhibited captopril transport, and vice versa, in a competitive manner and exhibited an approximately 1/3-fold lower Ki value for captopril compared with that for VY; indicating that both compounds compete for the same membrane transport pathway. A 50% decrease in plasma captopril levels by combined administration with VY supported that the attenuation of the BP lowering effect was due to inhibition of captopril uptake by VY. Consequently, our findings suggest that subjects treated with ACE inhibitors for hypertension should avoid combined-intake with antihypertensive foods that are rich in small peptides due to the competitive inhibition of drug uptake by these peptides.

UR - http://www.scopus.com/inward/record.url?scp=33751005583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751005583&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2006.08.013

DO - 10.1016/j.lfs.2006.08.013

M3 - Article

C2 - 16959271

AN - SCOPUS:33751005583

VL - 79

SP - 2492

EP - 2498

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 26

ER -